Latest news with #AHEL
Time of India
31-07-2025
- Business
- Time of India
Apollo entities seek CCI nod for recast plan
Apollo Group entities have sought the Competition Commission of India 's (CCI) approval for a composite restructuring plan that would eventually lead to the separate listing of the group's omnichannel pharmacy and digital health businesses within 18-21 months. The proposal involves the demerger of omnichannel pharmacy distribution, Apollo 24|7 digital platform and remote telehealth division of Apollo Hospitals Enterprise (AHEL) into a new company-Apollo Healthtech (AHTL). Explore courses from Top Institutes in Please select course: Select a Course Category CXO Project Management PGDM Cybersecurity Product Management Degree Leadership Technology Finance Public Policy Others Artificial Intelligence MBA Data Science Data Analytics Design Thinking others Management Operations Management healthcare MCA Digital Marketing Data Science Healthcare Skills you'll gain: Customer-Centricity & Brand Strategy Product Marketing, Distribution, & Analytics Digital Strategies & Innovation Skills Leadership Insights & AI Integration Expertise Duration: 10 Months IIM Kozhikode IIMK Chief Marketing and Growth Officer Starts on Apr 7, 2024 Get Details Skills you'll gain: Operations Strategy for Business Excellence Organizational Transformation Corporate Communication & Crisis Management Capstone Project Presentation Duration: 11 Months IIM Lucknow Chief Operations Officer Programme Starts on Jun 30, 2024 Get Details Skills you'll gain: Technology Strategy & Innovation Emerging Technologies & Digital Transformation Leadership in Technology Management Cybersecurity & Risk Management Duration: 24 Weeks Indian School of Business ISB Chief Technology Officer Starts on Jun 28, 2024 Get Details Skills you'll gain: Digital Strategy Development Expertise Emerging Technologies & Digital Trends Data-driven Decision Making Leadership in the Digital Age Duration: 40 Weeks Indian School of Business ISB Chief Digital Officer Starts on Jun 30, 2024 Get Details Subsequently, Keimed, another group entity that focusses on wholesale pharmacy business, will be merged into this new company. This will create a formidable listed omnichannel pharmacy distribution and digital health platform leader in India with ₹16,300 crore in revenues in FY25, AHEL had said in June. This combined entity was proposed to be listed in 18-21 months. According to the filing of the group entities with the antitrust regulator dated July 30, the new company will then acquire 74.5% shareholding of Apollo Medicals (AMPL) from existing shareholders in accordance with the applicable regulatory framework and a share purchase agreement already executed for this purpose. Manipal seeks nod too Live Events Separately, Manipal Hospitals , an arm of Manipal Health Enterprises, has sought the CCI clearance to acquire 100% of Sahyadri Hospitals in multiple tranches, according to a separate filing with the regulator dated July 30.
&w=3840&q=100)
Business Standard
01-07-2025
- Business
- Business Standard
Apollo eyes 20-23% growth in new co; says restructuring to unlock value
Apollo Hospitals Enterprise Ltd (AHEL) on Tuesday said its ongoing restructuring aims to unlock the value of its omni-channel pharmacy and digital businesses, while enhancing shareholder returns. The newly formed entity is expected to achieve a year-on-year growth rate of 22–23 per cent, driven by the e-pharmacy segment and other business verticals, with a revenue target of Rs 25,000 crore by FY27. The digital health platform is also expected to break even within the next financial year. On Monday, the Chennai-based AHEL announced plans to spin off its digital health and pharmacy distribution businesses into a separate entity, with plans to list the new entity within 18 to 21 months. As part of the restructuring, the company's omni-channel pharma and digital health business, Apollo HealthCo, will first be demerged from AHEL into a new entity, following which its pharma distribution arm, Keimed, will be merged into the new company. Its current revenue stands at around Rs 16,300 crore. The company has stated plans to achieve a revenue run rate of Rs 25,000 crore by FY27 with 7 per cent EBITDA margins, said Suneeta Reddy, Managing Director, Apollo Hospitals Enterprise. After the entire restructuring process—expected to be completed by the listing of the new company by February 2027—the new entity will include the digital health platform Apollo 24/7, the offline pharmacy business of Apollo HealthCo, Keimed, and the telehealth services business. 'We are looking at a growth of around 22 per cent to 23 per cent on a year-on-year basis. In the first two quarters—Q4 and Q1 of this year—we have been able to beat that number reasonably well, and I believe that traction is on. It will primarily come from the e-pharmacy business, wherein we have started touching around Rs 165 crore to Rs 170 crore on a month-on-month basis between the platform and some of the other supporting engines,' said Madhivanan Balakrishnan, Chief Executive Officer of Apollo HealthCo. 'Both the consult business and the diagnostic business, which we work very closely with Apollo Hospitals, are also showing an uptick. There are two more lines of business which we are adding—one is insurance, which is in the early stages; that will also contribute to growth, not just as a standalone line of business but also as a feeder into our primary pharmacy and healthcare lines of business. 'And third, this year we see a reasonable amount of GMV—also more than GMV—revenue coming from our monetisation initiatives. We are reasonably confident of 20 to 25 per cent growth between both AHEL as well as Keimed once it comes through,' Balakrishnan added.
Business Standard
01-07-2025
- Business
- Business Standard
Apollo Hospital rallies after board OKs demerger of digital & pharmacy units
Apollo Hospital Enterprise (AHEL) added 3.25% to Rs 7,477.95 after the company's board approved to spin-off its omnichannel pharmacy and digital health businesses through scheme of arrangement. The board of AHEL and its subsidiary, Apollo HealthCo granted in-principle approval for the demerger of Omnichannel Pharma and Digital Health business. The proposed structure enables direct access of omni-channel pharmacy and digital health business to the shareholders of AHEL. For every 100 shares of AHEL, the shareholders of AHEL will receive 195.2 shares of the new company, Apollo Healthtech enabling their direct participation in the value unlock. The proposed transaction will result in the creation of the largest, integrated omni channel healthcare eco-system with a FY25 revenue of approximately Rs 16,300 crore ($ 1.9 billion) in FY25. The Apollo Healthtech is expected to achieve a revenue run rate of Rs 25,000 crore ($2.9 billion) by FY27. Upon the effectiveness of the Scheme, Apollo Healthtech will become an Indian owned and controlled company (IOCC) and it will apply for listing on the stock exchanges. The listing is expected within 18 to 21 months. AHEL will retain 15% stake in the Apollo Healthtech to ensure an integrated, seamless, and comprehensive healthcare offering across the patient lifecycle. Upon becoming an IOCC, the Apollo Healthtech also proposes to consolidate the front-end pharmacy business by acquiring the remaining 74.5% stake in Apollo Medicals (AMPL), which owns 100% of APL. Dr Prathap C Reddy, chairman, Apollo Hospitals Group, said "Today's developments mark the beginning of the next chapter of Apollo Hospitals' relentless mission to bring healthcare of world-class standards within the reach of every individual. The omnichannel pharmacy business and integrated digital healthcare ecosystem will be a unique model to enable access to high-quality healthcare for millions of Indians. What Apollo Hospitals achieved for the creation of the private healthcare industry in India, this new entity will create for the digitally forward generation of tomorrow. We have the opportunity to make a positive difference to their lives and partner in their wellness pursuits. I wish both the teams all the best as they enter uncharted territory with infinite potential." Suneeta Reddy, managing director, Apollo Hospitals Enterprise said, "Apollo has always focused on growth, reach, and scale. We have carefully built our formats-of-care around the consumer at the centre. This comprehensive integrated network, overlaid with a strong digital layer, will allow us to create an impact of magnitude greater than could be achieved with a single format of care. AHEL will continue its focus on outstanding healthcare delivery, while the New Entity will accelerate its efforts on deepening customer engagement and penetration, with clear capital allocation outlays, growth plans and management teams driving both. Together, we will generate unparalleled value for the consumer, while making sure that all synergies and network effects stay intact, rooted in the Apollo ethos of quality and trust." Shobana Kamineni, executive chairperson, Apollo HealthCo said, "The New Entity, once integrated, will be a truly customer-focused healthcare leader, with capabilities across the value chain. Delivering medicines seamlessly from more than 7,000 physical stores, online delivery platform serving over 19,000 pincodes, with Keimed ensuring supply chain integrity, our aspiration is that we will serve over 100 million Indians with trusted quality and availability. With each business expected to record healthy rates of growth, we will continue to be the leader in this sector. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The company reported 53.5% jump in consolidated net profit to Rs 389.60 crore on 13.1% increase in revenue from operations to Rs 5,592.20 crore in Q4 FY25 over Q4 FY24.
Mint
01-07-2025
- Business
- Mint
Apollo Hospitals to list its pharmacy and digital health business in 18-21 months
Apollo Hospitals Enterprise Limited (AHEL) late on Monday announced plans to list its omnichannel pharmacy and digital health business in the next 18-21 months as part of a strategic reorganization. The company's board of directors has approved the demerger of its omnichannel pharma and digital health business, Apollo HealthCo, into a new entity—NewCo—through a composite scheme of arrangement. Following the demerger, Keimed, the wholesale pharmaceutical distributor that Apollo acquired last year, will be amalgamated with NewCo. Apollo Hospitals shareholders will have direct shareholding in the combined entity. For every 100 shares of AHEL, shareholders will receive 195.2 shares of the new entity, the company said. The proposed transaction will result in the creation of the largest, integrated omnichannel healthcare ecosystem with a FY25 revenue of ₹ 16,300 crore ($1.9 billion) in FY25, the company said. The new business, comprising Apollo 24/7, the digital health platform, the offline pharma distribution business, Keimed, and telehealth services, is expected to achieve a revenue run rate of ₹ 25,000 crores ($2.9 billion) by FY27. In an interview with Mint last week, Shobana Kamineni, executive chairperson of Apollo HealthCo, said that the entity is expected to hit a ₹ 30,000 crore valuation in the next five to six years, as it grows exponentially. The listing is expected within 18 to 21 months. NewCo will become an Indian owned and controlled company (IOCC) once the scheme is put into effect. NewCo plans to consolidate the front-end pharmacy business by acquiring the remaining 74.5% stake in Apollo Medicals Pvt. Ltd (AMPL), which owns 100% of Apollo HealthCo. This will enable the NewCo to participate fully in the business economics of retail pharmacies, the company said. AHEL will retain 15% stake in NewCo and will have one nominee director on the Board of NewCo.
&w=3840&q=100)
Business Standard
01-07-2025
- Business
- Business Standard
Apollo Hospitals shares hit record on plan to list pharmacy, digital biz
Shares of Apollo Hospitals Enterprise Ltd. surged over 4 per cent to hit a record high on Tuesday, after the company said it will spin off and separately list its digital health and pharmacy unit within 18 to 21 months. The hospital firm's stock rose as much as 4.42 per cent during the day to a life high of ₹7,569.5 per share. The stock pared gains to trade 3.5 per cent higher at ₹7,500 apiece, compared to a 0.22 per cent advance in Nifty 50 as of 9:46 AM. Shares of the company saw their steepest intraday gain since November 7 last year. The counter has fallen 2.8 per cent this year, compared to an 8.2 per cent advance in the benchmark Nifty 50. Apollo Hospitals Enterprise has a total market capitalisation of ₹1.08 trillion. Apollo Hospitals to list digital health, pharmacy unit Apollo Hospitals plans to demerge its omnichannel pharmacy distribution, Apollo 24|7 digital platform, and remote telehealth division into a new entity, according to an exchange filing on Monday. Simultaneously, Keimed Pvt Ltd will be merged into the same entity. This move will allow Apollo Hospitals shareholders to directly own shares in the newly created, integrated healthcare entity, the company said in the statement. The combined company is projected to have revenues of approximately ₹16,300 crore in the financial year 2024–25. It aims to reach a revenue run-rate of ₹25,000 crore by the end of the financial year 2026-27, with a gross merchandise value (GMV) of ₹28,000 crore and targeted Ebitda margins of around 7 per cent, according to the investor presentation report. The listing of the entity is expected to take place within 18 to 21 months. Under the scheme, shareholders of AHEL will receive 195.2 shares of the new company for every 100 shares held in AHEL. In addition, subject to regulatory approvals, AHEL also plans to increase the new entity's stake in Apollo Pharmacies Ltd by acquiring the remaining 74.5 per cent stake in Apollo Medicals Pvt. Ltd (AMPL), of which APL is currently a wholly owned subsidiary. JM Financial on Apollo Hospitals With approximately 6,600 outlets, 1.4 times that of the second-largest player, the company operates the largest pharmacy network in India. The integration of the Apollo 24|7 online platform and the merger with Keimed are expected to accelerate growth, enabling expansion in online sales and strengthening of private label offerings, the brokerage said. With a better product mix, realisation of synergies, and increased operating leverage, segmental Ebitda margins are projected to improve from 1.8 per cent to 6.5 per cent by financial year 2027–28, supported by a top-line compound annual growth rate (CAGR) of 20.2 per cent between financial years 2024–25 and 2027–28, it said. Apollo Hospitals Q4 results The company reported a consolidated net profit of ₹389.6 crore for the quarter ended March 31, 2025 (Q4 FY25), marking a growth of nearly 54 per cent from ₹253.8 crore in the year-ago period (Q4 FY24). Revenue from operations in Q4 FY25 stood at ₹5,592.2 crore, up around 13.11 per cent from ₹4,943.9 crore in Q4 FY24. On a quarter-on-quarter basis, revenue rose moderately from ₹5,526.9 crore in Q3 FY25.
